Actively Recruiting
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.
Led by Bristol-Myers Squibb · Updated on 2026-01-07
106
Participants Needed
1
Research Sites
47 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-986521 following single and multiple ascending doses of BMS-986521 in healthy adult participants, and to evaluate potential food effects on BMS-986521 exposure.
CONDITIONS
Official Title
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy males and females (assigned at birth) not of childbearing potential with no significant abnormalities in medical history, physical exam, ECG, or lab tests
- Body mass index between 18 and 32 kg/m2 and body weight of at least 50 kg
- For Part B/Cohort 11 only: stable cardiovascular conditions allowed if deemed suitable by investigator
You will not qualify if you...
- Significant medical conditions or history affecting drug absorption, distribution, metabolism, or excretion, or posing risk to participant
- History of rhabdomyolysis, cancer (except certain cured skin or cervical cancers), hematologic malignancy, or myelodysplastic syndrome
- Recent or current significant gastrointestinal disease, major surgery, or medical interventions affecting drug absorption, distribution, metabolism, or excretion (except appendectomy or cholecystectomy)
- Blood transfusion within 4 weeks prior to study
- Inability to tolerate oral medication or venous access
- Other protocol defined inclusion/exclusion criteria apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CenExel ACT (Formerly Anaheim Clinical Trials; LLC)
Anaheim, California, United States, 92801
Actively Recruiting
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
F
First line of the email MUST contain the NCT# and Site #.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
12
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here